Form 4 for ETRA Electra Therapeutics, Inc.
Accepted 2026-09-21 18:14:36 ET · period of report 2026-09-21 · accession 0002153364-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-21 18:14 | 2026-09-21 | ETRA | Dong Quehuong (Kathy) | Pres, CEO, Dir | C - Cnv Deriv | — | +455.5K | 455.5K | New | — |
| D | 2026-09-21 18:14 | 2026-09-21 | ETRA | Dong Quehuong (Kathy) | Pres, CEO, Dir | C - Cnv Deriv | — | -455.5K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-21 | C | A | 455,484 | — | 455,484 | D | — | — | (F1) 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026. (F2) Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. |
| 2 | Derivative | Series A Convertible Preferred Stock | 2026-09-21 | C | D | 455,484 | — | 0 | D | — · — to — | 455,484 Common Stock | (F2) Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. (F1) 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026. (F2) Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. (F2) Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. (F2) Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. (F1) 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026. |